Search

Search Constraints

You searched for: Author/Creator Sznol, Mario

Search Results

1. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Issue 7 (July 2016)

2. Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. (December 2018)

3. RBTT-07. A PHASE 2 TRIAL OF PEMBROLIZUMAB AND BEVACIZUMAB IN MELANOMA BRAIN MET PATIENTS. (11th November 2019)

4. 420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study. (10th December 2020)

5. 420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study. (9th November 2020)

6. 21 Plasma-based proteomic profiling as a tool for predicting response to immunotherapy in melanoma patients. (10th December 2020)

7. 21 Plasma-based proteomic profiling as a tool for predicting response to immunotherapy in melanoma patients. (9th November 2020)

8. Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218). Issue 1 (23rd November 2020)

10. Pre-treatment patient selection for nivolumab benefit based on serum mass spectra. (4th November 2015)